Home > Cardiology > ACC 2022 > Heart Failure and Cardiomyopathy > Sotagliflozin SCORED MACE benefit

Sotagliflozin SCORED MACE benefit

Presented By
Prof. Deepak Bhatt, Brigham and Women's Hospital, USA
Conference
ACC 2022
Trial
Phase 3, SCORED
New analyses of the SCORED trial revealed that SGLT1/2 inhibitor sotagliflozin provides up to 23% risk reduction of major cardiovascular adverse events (MACE) in patients with type 2 diabetes, chronic kidney disease, and at high risk for cardiovascular disease (CVD). The phase 3 SCORED trial (NCT03315143) compared the treatment of sotagliflozin with placebo in 10,584 patients with type 2 diabetes and chronic kidney disease. The primary endpoint of risk of complex events such as cardiovascular death, heart failure hospitalisation, and emergency room visit for heart failure was met, and published last year, showing that sotagliflozin reduced the risk for cardiovascular outcomes [1]. At the ACC Scientific Session, Prof. Deepak Bhatt (Brigham and Women's Hospital, MA, USA) presented a pre-specified, secondary analysis of the SCORED results, looking specific...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on